BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Ranibizumab

Endophthalmitis

The SUSVIMO implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. In clinical trials, 2.0% of patients receiving an implant experienced an episode of endophthalmitis.


Patient Counseling Information

Package Inserts

Ranibixzumab

Updated October 2021